DEBRA CHARLES: Open Payments
NPI 1225819790 · OLDSMAR, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,310 in 101 payments from 13 companies in 2025. Trend: 2023 $878 · 2024 $3,420 · 2025 $2,310
Food & beverage: $2,310
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $562 |
| Neurocrine BioSciences, Inc. | 14 | $312 |
| Vanda Pharmaceuticals Inc. | 8 | $234 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $201 |
| Otsuka America Pharmaceutical, Inc. | 7 | $165 |
| Janssen Pharmaceuticals, Inc | 8 | $164 |
| E.R. Squibb & Sons, L.L.C. | 9 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $121 |
| Alkermes, Inc. | 5 | $104 |
| Lundbeck LLC | 4 | $98 |
Products named: VRAYLAR, INGREZZA, REXULTI, HETLIOZ, CAPLYTA, COBENFY, SPRAVATO, TRINTELLIX.
Industry payments across FL — which companies pay providers there.
